Metabolic Changes in Chronic Hepatitis C Patients Who Carry IFNL4-ΔG and Achieve Sustained Virologic Response With Direct-Acting Antiviral Therapy

Autor: Man Charurat, Benjamin Emmanuel, Laurence S. Magder, Thomas R. O'Brien, Ludmila Prokunina-Olsson, Shyam Kottilil, Samer S. El-Kamary, Colleen Hadigan, Cheryl Chairez, Kristen A Stafford, Henry Masur, Mary Ann McLaughlin
Rok vydání: 2019
Předmět:
Male
0301 basic medicine
medicine.medical_specialty
Genotype
Sustained Virologic Response
Hepatitis C virus
Human immunodeficiency virus (HIV)
medicine.disease_cause
Antiviral Agents
Gastroenterology
Major Articles and Brief Reports
03 medical and health sciences
0302 clinical medicine
Chronic hepatitis
Internal medicine
medicine
Humans
Immunology and Allergy
Aspartate Aminotransferases
Longitudinal Studies
Triglycerides
Retrospective Studies
biology
business.industry
Interleukins
Cholesterol
HDL
virus diseases
Alanine Transaminase
Cholesterol
LDL
Hepatitis C
Chronic
Middle Aged
medicine.disease
digestive system diseases
030104 developmental biology
Infectious Diseases
Alanine transaminase
Virologic response
biology.protein
Coinfection
Female
030211 gastroenterology & hepatology
business
Lipoprotein
Zdroj: J Infect Dis
ISSN: 1537-6613
0022-1899
DOI: 10.1093/infdis/jiz435
Popis: BackgroundClearance of hepatitis C virus (HCV) results in rapid changes in metabolic parameters early in direct-acting antiviral (DAA) therapy. Long-term changes after sustained virologic response (SVR) remain unknown.MethodsWe investigated longitudinal changes in metabolic and inflammatory outcomes in chronic hepatitis C (CHC) patients: low-density lipoprotein (LDL), high-density lipoprotein, triglycerides, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) using a general linear model for repeated measurements at 5 clinical time points and by human immunodeficiency virus (HIV) coinfection and IFNL4 genotype.ResultsThe mean LDL increased markedly during DAA therapy (pre-DAA, 86.6 to DAA, 107.4 mg/dL; P < .0001), but then it decreased to 97.7 mg/dL by post-SVR year 1 (P < .001 compared with DAA; P = .0013 compared with SVR). In patients who carry the IFNL4-ΔG allele, mean LDL increased during treatment, then decreased at post-SVR year 1; however, in patients with TT/TT, genotype did not change during and after DAA treatment. The mean ALT and AST normalized rapidly between pre-DAA and DAA, whereas only mean ALT continued to decrease until post-SVR. Metabolic and inflammatory outcomes were similar by HIV-coinfection status.ConclusionsChanges in LDL among CHC patients who achieved SVR differed by IFNL4 genotype, which implicates the interferon-λ4 protein in metabolic changes observed in HCV-infected patients.
Databáze: OpenAIRE
Externí odkaz: